Quantum Biopharma Class B Subordinate Voting Shares

QNTM

Market cap $29.8M

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzd™, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commercialization strategy. With the functional beverage market projected to reach $198 billion in 2026 and expected to grow at a 10.79% CAGR, Mr. Buzbuzian brings the vision and capital markets acumen required to capitalize on this unprecedented market opportunity. His mandate includes executing a nationwide rollout beginning with strategic market expansion into South Florida and Texas — two of America's most dynamic consumer markets, as well as listing the Company on a stock exchange.

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has formally submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Lucid-21-302 (Lucid-MS), its new drug candidate for the treatment of multiple sclerosis (MS). This milestone IND submission supports Quantum's planned Phase 2 clinical trial evaluating its first-in-class therapeutic treatment targeting demyelination, advancing Quantum BioPharma's strategic growth in the global neurological market.

Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelination Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelination

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028 Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028

unbuzzd Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover unbuzzd Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that it has closed an initial tranche (“First Tranche”) of the offering announced on March 10, 2026 and March 11, 2026 (collectively, the “Announcement NRs”) and has issued 3,750 Debenture Units (as defined in the Announcement NRs) for $3,750,000.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.